نتائج البحث - Sarina A. Piha‐Paul

تنقيح النتائج
  1. 1
    Safety and Antitumor Activity of the Anti–Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma

    Safety and Antitumor Activity of the Anti–Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma حسب Toshihiko Doi, Sarina A. Piha‐Paul, Shadia I. Jalal, Sanatan Saraf, Jared Lunceford, Minori Koshiji, Jaafar Bennouna

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours

    Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours حسب Sarina A. Piha‐Paul, P.N. Munster, Antoine Hollebecque, Guillem Argilés, Olav Dajani, Joyce Cheng, Ran Wang, A. Swift, Alessandra Tosolini, Shiva Gupta

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer

    Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer حسب Funda Meric‐Bernstam, Amber M. Johnson, Ecaterina E. Dumbrava, Kanwal Raghav, Kavitha Balaji, Michelle Bhatt, Rashmi K. Murthy, Jordi Rodón, Sarina A. Piha‐Paul

    منشور في 2018
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience

    Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience حسب Jennifer J. Wheler, Apostolia M. Tsimberidou, David S. Hong, Aung Naing, Gerald S. Falchook, Sarina A. Piha‐Paul, Siqing Fu, Stacy L. Moulder, Bettzy Stephen, Sijin Wen, Razelle Kurzrock

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer

    Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer حسب David S. Hong, Filip Janků, Aung Naing, Gerald S. Falchook, Sarina A. Piha‐Paul, Jennifer J. Wheler, Siqing Fu, Apostolia M. Tsimberidou, Michael Stecher, Prasant Mohanty, John Simard, Razelle Kurzrock

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer

    BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer حسب Gerald S. Falchook, Michael Millward, David S. Hong, Aung Naing, Sarina A. Piha‐Paul, Steven G. Waguespack, Maria E. Cabanillas, Steven I. Sherman, Bo Ma, Martin Curtis, Vicki Goodman, Razelle Kurzrock

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Impact of microRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer

    Impact of microRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer حسب Christian Rolfo, Daniele Fanale, David S. Hong, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Patrick Pauwels, Jan P. van Meerbeeck, Stefano Caruso, Viviana Bazan, Giuseppe Cicero, Antonio Russo, Elisa Giovannetti

    منشور في 2014
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Phase I Study of SYNB1891, an Engineered <i>E. coli</i> Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies

    Phase I Study of SYNB1891, an Engineered <i>E. coli</i> Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies حسب Jason J. Luke, Sarina A. Piha‐Paul, Theresa Medina, Claire F. Verschraegen, Mary Varterasian, Aoife M. Brennan, Richard J. Riese, Anna Sokolovska, James Strauss, David L. Hava, Filip Janků

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    <i>PIK3CA</i> Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials

    <i>PIK3CA</i> Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials حسب Filip Janků, Jennifer J. Wheler, Aung Naing, Gerald S. Falchook, David S. Hong, Vanda M. Stepanek, Siqing Fu, Sarina A. Piha‐Paul, J. Jack Lee, Rajyalakshmi Luthra, Apostolia M. Tsimberidou, Razelle Kurzrock

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy

    P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy حسب Rabih Said, David S. Hong, Carla L. Warneke, J. Jack Lee, Jennifer J. Wheler, Filip Janků, Aung Naing, Gerald S. Falchook, Siqing Fu, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Razelle Kurzrock

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

    Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study حسب Hyun Cheol Chung, Willeke Ros, Jean‐Pierre Delord, Ruth Perets, Antoîne Italiano, Ronnie Shapira‐Frommer, Lyudmila Manzuk, Sarina A. Piha‐Paul, Lei Xu, Susan Zeigenfuss, Scott K. Pruitt, Alexandra Léary

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses

    Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses حسب Apostolia M. Tsimberidou, Sijin Wen, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Siqing Fu, Sarina A. Piha‐Paul, Aung Naing, Filip Janků, Kenneth Aldape, Ye Yang, Razelle Kurzrock, Donald A. Berry

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

    A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors حسب Anthony W. Tolcher, Jordan Berlin, Jan Cosaert, John Kauh, Emily Chan, Sarina A. Piha‐Paul, Alex Amaya, Shande Tang, Kyla Driscoll, Richard Kimbung, Siva Rama Prasad Kambhampati, Ivelina Gueorguieva, David S. Hong

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway

    Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway حسب Jennifer J. Wheler, Stacy Moulder, Aung Naing, Filip Janků, Sarina A. Piha‐Paul, Gerald S. Falchook, Ralph Zinner, Apostolia M. Tsimberidou, Siqing Fu, David S. Hong, Johnique T. Atkins, Roman Yelensky, Philip J. Stephens, Razelle Kurzrock

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

    Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers حسب Jennifer J. Wheler, Filip Janků, Gerald S. Falchook, Tiffiny Jackson, Siqing Fu, Aung Naing, Apostolia M. Tsimberidou, Stacy Moulder, David S. Hong, Hui Yang, Sarina A. Piha‐Paul, Johnique T. Atkins, Guillermo Garcia‐Manero, Razelle Kurzrock

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials

    Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials حسب Roman Groisberg, David S. Hong, Behrang Amini, Kenneth R. Hess, Filip Janků, Sarina A. Piha‐Paul, Aung Naing, Siqing Fu, Robert S. Benjamin, Shreyaskumar Patel, Neeta Somaiah, Anthony P. Conley, Funda Meric‐Bernstam, Vivek Subbiah

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine

    Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine حسب Apostolia M. Tsimberidou, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Filip Janků, Aung Naing, Siqing Fu, Sarina A. Piha‐Paul, Carrie Cartwright, Russell R. Broaddus, Graciela M. Nogueras‐González, Patrick Hwu, Razelle Kurzrock

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors

    Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors حسب Blessie Elizabeth Nelson, Shaun O’Brien, Rahul A. Sheth, David S. Hong, Aung Naing, Xiao–Ping Zhang, Amy Xu, Lora Hamuro, Rasika Suryawanshi, D. J. McKinley, Ruslan D. Novosiadly, Sarina A. Piha‐Paul

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    <i>PIK3CA</i> Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

    <i>PIK3CA</i> Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors حسب Filip Janků, Apostolia M. Tsimberidou, Ignacio Garrido‐Laguna, Xuemei Wang, Rajyalakshmi Luthra, David S. Hong, Aung Naing, Gerald S. Falchook, John W. Moroney, Sarina A. Piha‐Paul, Jennifer J. Wheler, Stacy Moulder, Siqing Fu, Razelle Kurzrock

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

    Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative حسب Apostolia M. Tsimberidou, Nancy G. Iskander, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Siqing Fu, Sarina A. Piha‐Paul, Aung Naing, Filip Janků, Rajyalakshmi Luthra, Ye Yang, Sijin Wen, Donald A. Berry, Razelle Kurzrock

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: